NO20092005L - MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser - Google Patents

MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser

Info

Publication number
NO20092005L
NO20092005L NO20092005A NO20092005A NO20092005L NO 20092005 L NO20092005 L NO 20092005L NO 20092005 A NO20092005 A NO 20092005A NO 20092005 A NO20092005 A NO 20092005A NO 20092005 L NO20092005 L NO 20092005L
Authority
NO
Norway
Prior art keywords
carboxylic acid
piperidine
naphthalene
acid compounds
compounds
Prior art date
Application number
NO20092005A
Other languages
English (en)
Inventor
Leo Jacobus Jozef Backx
Marcel Viellevoye
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092005L publication Critical patent/NO20092005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen angår nye piperidin- eller piperazinsubstituerte tetrahydro-naftalene-1-karboksylsyrederivater som har apoB utsondring/MTP inhiberende aktivitet og medfølgende lipidsenkende aktivitet. Oppfinnelsen angår videre metoder for å fremstille slike forbindelser, farmasøytiske sammensetninger omfattende nevnte forbindelser så vel som anvendelsen av nevnte forbindelser som en medisin for behandlingen av aterosklerose, pankreatitt, fedme, hypertriglyseridmi, hyperkolesterolemi, hyperlipidemi, diabetes og type II diabetes.
NO20092005A 2006-10-24 2009-05-25 MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser NO20092005L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
NO20092005L true NO20092005L (no) 2009-06-04

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092005A NO20092005L (no) 2006-10-24 2009-05-25 MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser

Country Status (27)

Country Link
US (1) US8114880B2 (no)
EP (1) EP2076494B1 (no)
JP (1) JP5506085B2 (no)
KR (1) KR101415536B1 (no)
CN (1) CN101528695B (no)
AR (1) AR063517A1 (no)
AT (1) ATE475648T1 (no)
AU (1) AU2007310925B2 (no)
BR (1) BRPI0717357A2 (no)
CA (1) CA2664141C (no)
CL (1) CL2007003042A1 (no)
CY (1) CY1111010T1 (no)
DE (1) DE602007008124D1 (no)
DK (1) DK2076494T3 (no)
EA (1) EA016311B1 (no)
IL (1) IL198332A (no)
JO (1) JO2653B1 (no)
MX (1) MX2009004386A (no)
NO (1) NO20092005L (no)
NZ (1) NZ575615A (no)
PL (1) PL2076494T3 (no)
PT (1) PT2076494E (no)
SI (1) SI2076494T1 (no)
TW (1) TWI396688B (no)
UA (1) UA99109C2 (no)
WO (1) WO2008049806A1 (no)
ZA (1) ZA200902822B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
DE602007006833D1 (de) 2006-10-24 2010-07-08 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
ES2646835T3 (es) 2010-10-18 2017-12-18 Cerenis Therapeutics Holding Sa Compuestos, composiciones y procedimientos útiles para la movilización del colesterol
EP3587406B1 (en) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
WO2019221192A1 (ja) * 2018-05-15 2019-11-21 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
YU23499A (sh) 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
DE602007006833D1 (de) 2006-10-24 2010-07-08 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate

Also Published As

Publication number Publication date
AR063517A1 (es) 2009-01-28
CN101528695A (zh) 2009-09-09
PL2076494T3 (pl) 2011-01-31
ZA200902822B (en) 2010-07-28
MX2009004386A (es) 2009-05-08
AU2007310925B2 (en) 2012-07-26
JO2653B1 (en) 2012-06-17
KR20090075832A (ko) 2009-07-09
US8114880B2 (en) 2012-02-14
UA99109C2 (ru) 2012-07-25
TW200833680A (en) 2008-08-16
WO2008049806A1 (en) 2008-05-02
KR101415536B1 (ko) 2014-07-16
EA016311B1 (ru) 2012-04-30
CA2664141C (en) 2015-04-28
ATE475648T1 (de) 2010-08-15
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
SI2076494T1 (sl) 2010-11-30
CL2007003042A1 (es) 2008-05-02
EA200970398A1 (ru) 2009-08-28
CY1111010T1 (el) 2015-06-11
IL198332A0 (en) 2010-02-17
JP2010507615A (ja) 2010-03-11
CN101528695B (zh) 2013-07-17
NZ575615A (en) 2011-01-28
BRPI0717357A2 (pt) 2013-10-22
CA2664141A1 (en) 2008-05-02
EP2076494B1 (en) 2010-07-28
JP5506085B2 (ja) 2014-05-28
DK2076494T3 (da) 2010-11-08
DE602007008124D1 (de) 2010-09-09
TWI396688B (zh) 2013-05-21
EP2076494A1 (en) 2009-07-08
HK1136823A1 (en) 2010-07-09
AU2007310925A1 (en) 2008-05-02
IL198332A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
NO20092005L (no) MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser
JO2537B1 (en) Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins
NO20084874L (no) Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20084852L (no) MGLUR5 modulatorer V
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
DK2032534T3 (da) 4-[(3-fluorphenoxy)phenylmethyl]piperidinmethansulfonat: anvendelser, fremgangsmåder til syntese og farmaceutiske præparater
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
JO2478B1 (en) (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
NO20083853L (no) Nye forbindelser
BRPI0417469A (pt) bifenil carboxamidas substituìdas com n-aril piperidina
DE602007006833D1 (de) Mtp-inhibierende tetrahydronaphthalin-1-carbonsäurederivate
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20064601L (no) Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
PL1638959T3 (pl) 4-(Aminometylo)piperydynobenzamidy antagonistyczne względem 5HT4
ATE522530T1 (de) 2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
ATE449093T1 (de) Heterocyclisch substituierte 4-(aminomethyl)- piperidinbenzamide als 5ht4-antagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application